In the 10th month of the pandemic, coronavirus disease 2019 (COVID‐19) vaccination was given first to healthcare workers in Turkey after receiving emergency use approval from the Ministry of Health. This study, which was performed at the COVID‐19 reference center in Ankara (the capital of Turkey) aimed to evaluate the seroconversion rate of the CoronaVac vaccine. The anti‐spike immunoglobulin G response to the two‐dose vaccination was retrospectively examined in healthcare workers who had no previous history of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. The postvaccine seroconversion rate was investigated by measuring the antibody levels of healthcare workers who had received CoronaVac. Vaccination was administered as 600 SU in 28‐day intervals. The healthcare workers' anti‐SARS‐CoV‐2 immunoglobulin G levels were used to determine the seroconversion rate 2 months after the second dose of the vaccine. Of the healthcare workers, 22.9% (n = 155) were seronegative. The younger the age of the participant, the higher the level of anti‐SARS‐CoV‐2 immunoglobulin G. Furthermore, anti‐SARS‐CoV‐2 immunoglobulin G levels were much higher in women than men.